Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology

/ Portfolio News / By Karina Tin

Post navigation

← Previous Post

In The News

Featured news from our team and portfolio

The Column Group Raises Over $400 Million For Its New Fund, TCG Labs-Soleil

The Column Group launches a novel ‘venture-biotech’ model, creating an integrated ecosystem to exclusively fund, discover, and develop single-asset biologic therapies.

View all News

Portfolio News

05.29.25

Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual meeting

05.28.25

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

05.27.25

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

05.27.25

Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into a Worldwide Licensing Agreement for KLK2-Directed T-Cell Engager in Metastatic Prostate Cancer

05.27.25

Circle Pharma’s Preclinical Data on CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

05.22.25

Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting

Meet TCG
Our Portfolio
In The News
Join Our Ecosystem
Contact Us
Investor Login

Meet TCG
Join Our Ecosystem
Our Portfolio
Contact Us
In The News
Investor Login

Scroll to Top